Wall Street is positive on Bolt Biotherapeutics Inc (BOLT). On average, analysts give the stock a Buy rating. The average price target is $8.666, which means analysts expect the stock to climb by 293.91% over the next twelve months. That average ranking earns the stock an Analyst Rating of 23, which is better than 23% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating BOLT a Buy today. Find out what this means to you and get the rest of the rankings on BOLT!